Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202876 | 0.88 | ADRB2 (0.37) | ADRB2ADRB1NR3C2 | |
| SCHEMBL8195296 | 0.83 | BRD4 (0.43) | BRD4CREBBPL3MBTL1ADRB2ADRB1 | |
| SCHEMBL8189703 | 0.83 | L3MBTL1 (0.41) | BRD4CREBBPL3MBTL1NR3C2DRD2 | |
| SCHEMBL8189655 | 0.82 | L3MBTL1 (0.38) | BRD4CREBBPL3MBTL1RPS6KA1ADRB2 | |
| SCHEMBL8189695 | 0.80 | ADRB2 (0.36) | ADRB2ADRB1NR3C2 | |
| SCHEMBL8200742 | 0.79 | NR3C2 (0.50) | BRD4CREBBPL3MBTL1ADRB2ADRB1 | |
| SCHEMBL8196981 | 0.79 | PARP1 (0.40) | BRD4CREBBPL3MBTL1RPS6KA1NR3C2 | |
| SCHEMBL8202568 | 0.79 | RPS6KA1 (0.39) | BRD4CREBBPL3MBTL1RPS6KA1ADRB2 | |
| SCHEMBL14080051 | 0.79 | IL4I1 (0.39) | ADRB2ADRB1NR3C2PARP1 | |
| SCHEMBL13181783 | 0.76 | PARP1 (0.37) | ADRB2ADRB1NR3C2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | BRD4 256/4885CREBBP 2453/4885L3MBTL1 4791/4885 |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | BRD4 380/4885CREBBP 3476/4885L3MBTL1 4720/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | BRD4 338/4885CREBBP 3053/4885L3MBTL1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.